Edward Hill, MD
Neurology · Winston Salem, NCNPI 1992795785
Payments from drug & device makers
Across 2,504 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$7K
- AstraZeneca$6K
- AbbVie$4K
- Mallinckrodt Hospital Products Inc.$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Abbott$2K
- plus $25K from 54 others
What the payments were for
- Speaking & faculty fees$13,99828%
- Travel & lodging$1,3783%
- Food & beverage$34,07269%
- Education$2831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,732 in reported general payments places this provider in the 80th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 29 | $1,902,089 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 80 | $1,303,170 |
| RystiggoRozanolixizumab-Noli | 25 | $1,019,082 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 54 | $983,400 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 39 | $767,053 |
| IngrezzaValbenazine Tosylate | 67 | $586,363 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $305,219 |
| NuplazidPimavanserin Tartrate | 47 | $231,739 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $185,889 |
| AustedoDeutetrabenazine | 11 | $144,106 |
| Kesimpta PenOfatumumab | 14 | $139,385 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $115,184 |
| Austedo XrDeutetrabenazine | 14 | $112,783 |
| BotoxOnabotulinumtoxina | 94 | $95,995 |
| QuliptaAtogepant | 81 | $92,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $257 | $1,303,17080 claims |
| CSL BehringPrivigen, Hizentra | $136 | $1,288,61971 claims |
| UCB, Inc.Rystiggo, Briviact | $1,683 | $1,038,87539 claims |
| PfizerOctagam, Nurtec Odt, Lyrica, Eliquis | $636 | $842,04598 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,534 | $586,36367 claims |
| AbbVieBotox, Qulipta, Ubrelvy, Savella, Linzess | $3,665 | $271,978263 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $2,370 | $256,88925 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,608 | $231,73947 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $473 | $185,88911 claims |
| BiogenVumerity, Avonex (4 Pack) | $1,607 | $171,45322 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $1,600 | $70,31827 claims |
| MDD US Operations, LLCGocovri | $537 | $57,85918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 566 neurology providers in North Carolina.
Other neurology in Winston Salem
- Mitchell IsaacWinston Salem$2.2M
- Roy StrowdWinston Salem$937K
- Mustafa SiddiquiWinston Salem$917K
- Rachana Gandhi MehtaWinston Salem$916K
- Michael CartwrightWinston Salem$229K
- Mohammad BolouriCharlotte$16.6M
- Katherine PetersDurham$11M
- John ScagnelliRaleigh$9.3M
- T RaoCharlotte$4M
- Pramod SethiGreensboro$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.